Fig. 1: OS in the subset of PSA-matched African American and Caucasian men with mCRPC treated with sipuleucel-T in PROCEED for all included patients.

Median OS estimates indicated by vertical dash-dot lines. CI confidence interval, HR hazard ratio, OS overall survival, PSA prostate-specific antigen.